Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy.

Yervoy (ipilimumab) - BMS

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

dacarbazine - Generic mfg.

http://www.ncbi.nlm.nih.gov/pubmed/42697593

Andriy Moshyk; Everardo D Saad; James Larkin; Marc Buyse; Murat Kurt; Peter Mohr; Pierre Squifflet

Sep 5, 2026